Africa’s rapidly growing youth population and expanding digital connectivity are positioning the continent’s creative industries as ...

We share untold stories and personal memories of Quentin Willson from the final week we spent with him in 2024. This episode of the BCG Therapy Podcast is a heartfelt tribute to Quentin Willson ...

Relmada Therapeutics Inc. RLMD shares are up during Monday’s premarket session following the release of promising interim ...

LEGEND pivotal cohort update planned for a spring 2026 medical conference12-month complete response data from LEGEND pivotal cohort expected in 2H 2026Biologics License Application (BLA) submission ...

Relmada Therapeutics (RLMD) stock jumped 31% after Phase 2 bladder cancer trial showed 76% response rate and company secured $160M in funding.

New report finds McKinsey layoffs have reshuffled employer brand power as graduates cite AI fears, 70-hour weeks, and ...

Africa is home to the world`s youngest and fastest growing population, with nearly 890-million people under the age of 25. This youth cohort represents both a powerful source of demand and a deep pool ...

The Ministry of Health has announced a nationwide shortage of the rotavirus vaccine given to infants, following delays in global supply. In a statement released on March 5, 2026, Cabinet Secretary ...

OpenAI this week announced multi-year partnerships with Boston Consulting Group, McKinsey & Company, Accenture, and Capgemini ...

The study is being conducted by management consulting firm Kearney and has been commissioned by the MoD’s Department of Defence Production (DDP) — which oversees all 16 defence public sector units ...

Investing.com -- Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares rose 25% Monday following the company’s announcement of 12-month interim data from its Phase 2 trial evaluating NDV-01 in patients with ...

ImmunityBio recently reported full-year 2025 results showing revenue rising to US$113.29 million while net loss narrowed to US$351.4 million, driven largely by the commercial rollout of ANKTIVA and ...